Commercialization of iPS Cells
The Ministry of Health, Labour and Welfare (MHLW) gave a greenlight for commercialization of induced pluripotent stem (iPS) cell which received Nobel Prize in Physiology or Medicine in 2012. It marked an important development in generative medicine in Japan, which the government of Japan promote as a country with advanced medical technology, even though it is a provisional license. Professor of Kyoto University, Shin-ya Yamanaka, was successful in producing a cell that had ability of differentiation into many cells and copying itself in 2006. It was expected to be used for medical treatment for serious disease of heart or Parkinson’s disease. Nobel committee approved the significance of Yamanaka’s achievement in identification of iPS cells as contribution to medical treatment of intractable diseases or development of new medicine for remedy. A subcommittee of MHLW decided to approve two kinds of pharmaceuticals that used iPS cells, encouraging medi...